Warby Parker Inc. (WRBY) Stock Forecast Nov. 6, 2026
Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · NYSE
Warby Parker Inc. (WRBY) stock forecast summary
Our AI scores Warby Parker Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Warby Parker Inc. is a mid-cap company with a market capitalization of $3.23B. It ranks number 4 by market capitalization among the 8 Ophthalmic Goods issuers in our coverage with a current forecast.
For WRBY, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 4.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 12.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, WRBY included.
WRBY price chart and AI forecast
How WRBY ranks among 5150 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Warby Parker Inc. (WRBY) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Ophthalmic Goods peers listed below that report each metric.
Valuation & Market
| Metric | WRBY | Rank |
|---|---|---|
| Market Cap | $3.23B | 4/8 |
| P/B Ratio | 9.11x | 1/7 |
| EPS | $0.00 | – |
| Book Value/Share | $2.86 | – |
| Revenue/Share | $7.56 | – |
| FCF/Share | $0.17 | – |
Profitability & Margins
| Metric | WRBY | Rank |
|---|---|---|
| ROE | 3.9% | 2/5 |
| Gross Margin | 54.8% | 5/6 |
| Operating Margin | 0.2% | 5/6 |
| Net Margin | 1.6% | 2/5 |
| EBT Margin | 1.1% | 4/6 |
| Tax Rate | 27.6% | – |
Financial Health
| Metric | WRBY | Rank |
|---|---|---|
| Current Ratio | 2.26x | 4/7 |
| Quick Ratio | 1.97x | 4/7 |
| D/E Ratio | 0.93x | 3/8 |
| Interest Coverage | 45.6x | 1/6 |
| Working Capital | $204M | 5/7 |
Cash Flow
| Metric | WRBY | Rank |
|---|---|---|
| Operating Cash Flow | $102M | 4/7 |
| Free Cash Flow | $21M | 4/6 |
| Capital Spending | -$81M | 4/6 |
| OCF Growth YoY | -5.0% | – |
| FCF Growth YoY | -43.7% | – |
| FCF/Sales | 2.3% | 6/6 |
| CapEx/Sales | 8.7% | 1/6 |
Operational Efficiency
| Metric | WRBY | Rank |
|---|---|---|
| Receivables Turnover | 438.4x | 1/7 |
| Inventory Turnover | 9.1x | 1/6 |
| Fixed Assets Turnover | 4.4x | 5/7 |
| Days Sales Outstanding | 1 days | 7/7 |
| Days Inventory | 40 days | 6/6 |
| Payables Period | 25 days | 5/5 |
| Cash Conversion Cycle | 16 days | 5/5 |
Income Statement
| Metric | WRBY | Rank |
|---|---|---|
| Total Revenue | $935M | 5/8 |
| Operating Income | $2M | 4/6 |
| Net Income | $14M | 2/5 |
| SG&A Expense | $510M | 5/8 |
| Cost of Goods Sold | $423M | 3/6 |
Dividend & Shareholder Information
| Metric | WRBY | Rank |
|---|---|---|
| Shares Outstanding | 124M | – |
| Net Income Growth | 292.4% | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $366M | 53.6% of assets |
| Cash & Short-term Investments | $288M | 42.2% of assets |
| Accounts Receivable | $2M | 0.3% of assets |
| Inventory | $46M | 6.8% of assets |
| Total Liabilities | $329M | 48.1% of assets |
| Short-term Debt | $134M | 19.6% of assets |
WRBY quarterly financials and insider trading
Warby Parker Inc. (WRBY) industry peers
Companies classified under the same SEC industry code as Warby Parker Inc. (Ophthalmic Goods): 8 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up freeWhere WRBY sits on the market map
Warby Parker Inc. (WRBY) stock news
Loading...
Warby Parker Inc. (WRBY) stock forecast FAQ
What is the Warby Parker Inc. (WRBY) stock forecast?
Our AI scores Warby Parker Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Warby Parker Inc. stock predictions?
For WRBY, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 4.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 12.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Warby Parker Inc. forecasts updated?
Warby Parker Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Which companies are Warby Parker Inc.'s industry peers?
8 issuers in our coverage, WRBY included, share the SEC industry code Ophthalmic Goods. The largest are: Alcon Inc (ALC), Cooper Companies, Inc. (COO), Bausch & Lomb Corp (BLCO), National Vision Holdings, Inc. (EYE), Staar Surgical Co (STAA), Rxsight, Inc. (RXST).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.